CuroNZ is a clinical-stage neurotherapeutics company focused on improving the quality of life for patients with severe neurological conditions, particularly children and adults suffering from epilepsy. Their primary therapeutic candidate, NRP2945, is a modified naturally occurring molecule that targets the CXCR4 receptor complex to control seizure activity while also addressing comorbidities associated with conditions like Lennox-Gastaut Syndrome and drug-resistant Temporal Lobe Epilepsy. NRP2945 is administered through subcutaneous injections every other day, demonstrating a favorable safety profile with minimal adverse effects, making it a well-tolerated option for patients.

The company employs innovative methodologies in its research and development, including a phenotypic brain tissue assay to identify compounds that promote neurogenesis in vulnerable brain regions. This approach has led to the discovery of Neural Regeneration Peptides (NRPs), which have shown potential in regenerating thalamic neurons that are often compromised in patients with epileptic encephalopathy. CuroNZ's clinical trials, including a successful Phase I safety trial and a Phase IIa trial for Absence Epilepsy, have indicated that NRP2945 can achieve significant seizure reduction and even freedom in many patients, highlighting its promise as a transformative treatment in the field of neurotherapeutics.

New Zealand

Curonz is a clinical stage biotechnology company with a patent portfolio and a focus on developing Neural Regeneration Peptides (NRPs) for various neurological conditions such as Lennox-Gastaut Syndrome (LGS) and Amyotrophic Lateral Sclerosis (ALS). The company aims to transform the Quality of Life of severely neurologically affected children and adults through its drug candidates.

CuroNZ

Company Details